ALLIANCE PHARMA PLC

Report Publication Announcement • Feb 4, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1638Z

Alliance Pharma PLC

04 February 2014

For immediate release	4 February 2014

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Notification of Preliminary Results

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its preliminary results for the year ended 31 December 2013 on Wednesday 26 March 2014.

A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For more information, or to register attendance, please contact Buchanan on 020 7466 5000.

For further information:

### Alliance Pharma plc	### + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
### Buchanan	### + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLLFIEFTIVIIS